Skip to main content


Section edited by Carlo Agostini

  1. Biologics are currently one of the main treatment options for a number of diseases. The IgG4 monoclonal antibody dupilumab targets the Interleukin-4 receptor alpha chain, thus preventing the biological effects...

    Authors: Eustachio Nettis, Luisa Brussino, Vincenzo Patella, Laura Bonzano, Aikaterini Detoraki, Elisabetta Di Leo, Maria Maddalena Sirufo, Cristiano Caruso, Fabio Lodi Rizzini, Mariaelisabetta Conte, Mona-Rita Yacoub, Massimo Triggiani, Erminia Ridolo, Luigi Macchia, Giovanni Rolla, Raffaele Brancaccio…
    Citation: Clinical and Molecular Allergy 2022 20:6
  2. This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects.

    Authors: Eustachio Nettis, Lucia Masciopinto, Elisabetta Di Leo, Nicola De Candia, Marcello Albanesi, Danilo Di Bona, Nicola Quaranta and Luigi Macchia
    Citation: Clinical and Molecular Allergy 2021 19:9
  3. Asthma is a chronic disease characterized by airway hyperresponsiveness, inflammation and mucus production. In Type 2 asthma, two phenotypic components are often co-expressed (eosinophilic and allergic). Eleva...

    Authors: Giorgio Walter Canonica, Francesco Blasi, Nunzio Crimi, Pierluigi Paggiaro, Alberto Papi, Francesca Fanelli, Annalisa Stassaldi and Gianluca Furneri
    Citation: Clinical and Molecular Allergy 2021 19:5
  4. Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic refractory disease. Provided that steroids represent the gold standard as a first line treatment, many immune s...

    Authors: Francesco Cinetto, Nicolò Compagno, Riccardo Scarpa, Giacomo Malipiero and Carlo Agostini
    Citation: Clinical and Molecular Allergy 2015 13:19

Annual Journal Metrics

  • 2022 Citation Impact
    0.927 - SNIP (Source Normalized Impact per Paper)
    0.583 - SJR (SCImago Journal Rank)

    2023 Speed
    191 days submission to accept (Median)

    2023 Usage 
    108 Altmetric mentions